Miltefosine Dosing for Kala Azar (Visceral Leishmaniasis)

Standard Dosing Regimen

The recommended dose of miltefosine for treating kala azar (visceral leishmaniasis) is 2.5 mg/kg/day for 28 consecutive days, with a maximum daily dose of 150 mg, as recommended by the Clinical Infectious Diseases guidelines 1, 2
For patients weighing 30-44 kg, the standard dosing regimen is 50 mg twice daily (total 100 mg/day) for 28 consecutive days, as recommended by the Clinical Infectious Diseases guidelines 2
For patients weighing ≥45 kg, the standard dosing regimen is 150 mg daily (in 3 divided doses of 50 mg) for 28 consecutive days, as recommended by the Clinical Infectious Diseases guidelines 2
Doses should be taken with food to minimize gastrointestinal side effects, as recommended by the Clinical Infectious Diseases guidelines 2

The FDA approval is limited to patients ≥12 years of age who weigh ≥30 kg, as stated by the Clinical Infectious Diseases guidelines 2
Use in children <12 years or <30 kg is considered off-label in the United States, according to the Clinical Infectious Diseases guidelines 2
Young children (2-11 years) may have lower plasma drug exposure and potentially lower cure rates compared to adults, as reported by the Clinical Infectious Diseases guidelines 2
A dosing algorithm with nonlinear, allometric scaling based on fat-free mass has been proposed for children, though the maximum daily dose remains 150 mg, as recommended by the Clinical Infectious Diseases guidelines 2

Miltefosine is contraindicated in pregnancy due to potential fetotoxicity, as stated by the Clinical Infectious Diseases guidelines 1
Breastfeeding women should not breastfeed during treatment or for 5 months after treatment, as recommended by the Clinical Infectious Diseases guidelines 1

Miltefosine has demonstrated excellent cure rates in visceral leishmaniasis in India, Nepal, and Bangladesh, as reported by the Clinical Infectious Diseases guidelines 3

Combination therapy with liposomal amphotericin B has shown promising results, as reported by the Clinical Infectious Diseases guidelines 4
A single dose of liposomal amphotericin B (5 mg/kg) followed by 7-14 days of miltefosine showed 96-98% cure rates, as reported by the Clinical Infectious Diseases guidelines 4
Combination therapies may reduce treatment duration, decrease toxicity, and potentially reduce the development of drug resistance, as stated by the Clinical Infectious Diseases guidelines 4

Patients with HIV co-infection may have lower cure rates and higher relapse rates, as reported by the Clinical Infectious Diseases guidelines 5, 6
In Ethiopia, a study showed miltefosine (100 mg/day for 28 days) was safer but less effective than sodium stibogluconate in HIV-prevalent populations, as reported by the Clinical Infectious Diseases guidelines 5

Doses <2 mg/kg/day are associated with lower response rates, as stated by the Clinical Infectious Diseases guidelines 2
Patients weighing >60 kg receive <2.5 mg/kg/day using standard dosing, which may affect efficacy, as reported by the Clinical Infectious Diseases guidelines 2
Poor compliance with the full 28-day course may lead to treatment failure and potential drug resistance, as stated by the Clinical Infectious Diseases guidelines 3
Contraindication in pregnancy must be strictly observed due to potential fetotoxicity, as recommended by the Clinical Infectious Diseases guidelines 1

The World Health Organization recommends a combination of liposomal amphotericin B and miltefosine for the treatment of visceral leishmaniasis, with cure rates of 96-98% 7
For HIV-coinfected patients, the Centers for Disease Control and Prevention suggests a combination of miltefosine and sodium stibogluconate for 30 days 7
The Infectious Diseases Society of America recommends combination therapies to reduce treatment duration, decrease toxicity, and potentially reduce the development of drug resistance 7

The American Society of Tropical Medicine and Hygiene suggests considering higher doses of liposomal amphotericin B (total dose: 40 mg/kg) for patients with HIV co-infection 7
The National Institutes of Health recommends considering combination therapy (e.g., miltefosine plus sodium stibogluconate) for patients with HIV co-infection 7